<DOC>
	<DOCNO>NCT00553423</DOCNO>
	<brief_summary>To evaluate role lactulose prevention clinically overt hepatic encephalopathy ( HE ) set acute upper gastrointestinal bleeding cirrhotic patient</brief_summary>
	<brief_title>Lactulose Prevention Hepatic Encephalopathy Cirrhotic Patients With Upper Gastrointestinal Hemorrhage</brief_title>
	<detailed_description>Variceal hemorrhage occur 25 35 % patient cirrhosis account 80 90 % bleed episodes patient . Around 25-30 percent patient develop hepatic encephalopathy . Development hepatic encephalopathy patient gastrointestinal bleed cause increase morbidity high hospital cost patient . To date randomize trial do term prevention encephalopathy gastrointestinal hemorrhage . One trial compare lactulose combination antibiotic mannite , show equal efficacy group . No study do evaluate efficacy lactulose prevention encephalopathy patient . We hypothesize prophylactic use Lactulose decrease risk development hepatic encephalopathy upper GI bleed cirrhotics .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<criteria>Age &gt; 18 year All acute gastrointestinal bleeding cirrhotics without hepatic encephalopathy time admission ER Increased Î±fetoprotein level/ Documented hepatoma Portal hepatic vein thrombosis Largevolume tense ascites require repeat therapeutic paracentesis Serious recurrent ongoing co morbid illness ( e.g. , severe renal , cardiac , respiratory failure ; sepsis ) Pregnancy Not willing give consent participate study Patients unable read write ER arrival time &gt; 12 hr index bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>